J Korean Neurol Assoc.
2021 Nov;39(4):287-297. 10.17340/jkna.2021.4.4.
Biomarker in Parkinson’s Disease: Clinical and Biochemical Biomarker
- Affiliations
-
- 1Department of Neurology, Kangdong Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea
- 2Department of Neurology, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea
- KMID: 2521857
- DOI: http://doi.org/10.17340/jkna.2021.4.4
Abstract
- Parkinson’s disease is a neurodegenerative disease compromising progressive motor and non-motor features for a long disease course. Although many drugs controlling parkinsonian symptoms were discovered, treatment with disease-modifying or halting effect was not developed to date. The exploration of reliable biomarkers would be helpful for better predicting disease progression and thereby successful development of disease-modifying therapy. In this review, we will review the clinical biomarkers in the prodromal stage and biomarkers using biological tissue in Parkinson’s disease.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease
- Urinary Biomarkers for Neurodegenerative Diseases
- Imaging of Dopaminergic System in Movement Disorders
- Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges
- Serum miR-3620-3p as a Novel Biomarker for Ankylosing Spondylitis
